Pas de connexion internet — affichage de la version enregistrée de la page.

Exelixis Inc

USUSD
← Vers le screener

Exelixis Inc (US:EXEL) — Biotechnology: Biological Products (No Diagnostic Substances). Nombre de places boursières sur lesquelles les actions de la société sont cotées : 3. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site web
exelixis.com
Relations avec les investisseurs
ir.exelixis.com/
Secteur
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Siège social
South San Francisco, United States
PDG
Dr. Michael M. Morrissey Ph.D.
Employés
1 077
Fondée
1994
Actions en circulation
247.78 M au 2026-07-27
Flottant
213.6 M
Capitalisation boursière
14.36 Md USD
Initiés
1.85%
Investisseurs institutionnels
106.81%
Secteur d'activité (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
US30161Q1040
LEI
254900PJQB59O2O95R37
Description

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Bourses et tickers

BourseTickerDevisePrixType
US USA StocksEXEL principaleUSD59.02 +0.99%actions ordinaires
LSE London Stock Exchange0IJO IOBUSD59.69 +0.00%actions ordinaires
MI Borsa Italiana (Milan)1EXEL secondaireEUR52.01 -0.27%actions ordinaires

Cours sur 3 mois

jour de hausse jour de baisse date de détachement du dividende date de versementSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Dividendes

Aucun versement de dividendes n'a été trouvé (vérifié le 09.10.2026). L'entreprise ne verse probablement pas de dividendes.

Actualités de cette semaine

Pas encore d'actualités du site de l'entreprise.

publicité

Principaux actionnaires

DétenteurParticipationActionsDate du rapport
Blackrock Inc.11.73%29.08 M2026-06-30
Farallon Capital Managem…5.44%13.47 M2026-06-30
Renaissance Technologies…5.42%13.43 M2026-06-30
Vanguard Portfolio Manag…4.86%12.04 M2026-06-30
AQR Capital Management,…4.45%11.02 M2026-06-30
Vanguard Capital Managem…4.42%10.95 M2026-06-30
State Street Corporation4.02%9.97 M2026-06-30
Fuller & Thaler Asset Ma…3.6%8.93 M2026-06-30
iShares Trust-iShares Co…3.55%8.8 M2026-08-31
LSV Asset Management3.29%8.15 M2026-06-30
Geode Capital Management…3.09%7.65 M2026-06-30
VANGUARD INDEX FUNDS-Van…3.06%7.58 M2026-06-30
Capitol Series Trust-Ful…2.84%7.04 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.21%5.47 M2026-06-30
MORRISSEY MICHAEL M (Chi…≈1.37%3.38 M2026-05-18
VANGUARD INDEX FUNDS-Van…1.27%3.16 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.16%2.88 M2026-06-30
Invesco Exchange-Traded…1.12%2.78 M2026-08-31
SPDR SERIES TRUST-State…0.8%1.99 M2026-08-31
SPDR S&P MIDCAP 400 ETF…0.74%1.84 M2026-08-31
iShares Trust-iShares Bi…0.74%1.82 M2026-08-31
PAPADOPOULOS STELIOS B (…≈0.48%1.2 M2026-05-27
SENNER CHRISTOPHER J. (C…≈0.39%955 0402026-05-18
HESSEKIEL JEFFREY J (Gen…≈0.28%694 3952025-05-15
AFTAB DANA T. (Officer)≈0.24%600 5762026-05-26
PETERSON AMY C (Officer)≈0.19%465 3932025-05-16
HALEY PATRICK JOSEPH (Of…≈0.14%357 6382026-05-20
WYSZOMIERSKI JACK L (Dir…≈0.11%284 3842026-06-01
POSTE GEORGE H (Director…≈0.05%127 1992026-05-27
JOHNSON DAVID EDWARD (Di…——2025-11-25